We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cambridge Isotope Laboratories & MRM Proteomics Sign Exclusive Agreement
News

Cambridge Isotope Laboratories & MRM Proteomics Sign Exclusive Agreement

Cambridge Isotope Laboratories & MRM Proteomics Sign Exclusive Agreement
News

Cambridge Isotope Laboratories & MRM Proteomics Sign Exclusive Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cambridge Isotope Laboratories & MRM Proteomics Sign Exclusive Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cambridge Isotope Laboratories, Inc. is working together with MRM Proteomics, to improve quantitative proteomics through quality control and standardization. Many researchers in academics and the life science industries are striving to discover and validate protein and metabolite biomarkers that can be used to diagnose and predict the progression or treatment for disease, and mass spectrometry is commonly used in these studies. A common problem in such studies is that the sample sets are small due to the complexity of the experiments, and each laboratory has its own procedures for calibrating and qualifying the mass spectrometry platforms used. To validate biomarkers discovered in these smaller studies, larger studies must be performed under rigorously controlled conditions.

To support standardized quantitative proteomics workflows for biomarker discovery and validation, MRMP has developed assays using Stable Isotope Standard (SIS) labeled peptides as standards to enable robust and precise quantitation of protein biomarkers, in a highly multiplexed workflow using mass spectrometry, known in its abbreviated form as LC-MRM/MS. MRMP is now making sets of these SIS standards available in PeptiQuant™ kits that contain all reagents and methods required to perform experiments to quantitate proteins, with the first Biomarker Assessment Kit (BAK) allowing for 76 proteins associated with various diseases to be quantitated in a single experiment. To further standardize and enhance the quality of quantitative proteomics experiments, MRMP is also providing PeptiQuant QC kits to allow researchers to qualify their workflows and LC-MRM/MS platforms.  Under the terms of the agreement, CIL will have exclusive selling rights to MRMP’s PeptiQuant™ kits used for quantitative proteomics, and CIL will provide distribution for the products worldwide.  CIL and MRMP also plan to extend the product range with further BAK kits for specific disease areas and into quantitative metabolomics for use in the discovery and validation of metabolic biomarkers.

Gary Kruppa, CEO of MRMP, stated, “CIL is the world's leading producer and supplier of stable isotope-enriched small molecules to the mass spectrometry community. In fact, we use CIL isotopically enriched amino acids in the synthesis of the SIS included in our PeptiQuant kits.  CIL knows our market and customers already and has excellent sales and distribution channels worldwide. We are delighted to be working with a company that is so well regarded and so well suited to sell and distribute our PeptiQuant™ kits.”

Maureen Duffy, VP of Sales and Marketing at CIL, commented, "CIL has taken a serious approach in providing researchers the tools to aid in biomarker discovery and development. MRMP's strong technical know-how and leadership in both quantitative proteomics and clinical diagnostics fits well into CIL's portfolio. We are looking forward to working with MRM and to make these kits accessible to researchers worldwide."

Advertisement